In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses factors that are contributing to ongoing supply issues and if prices for these therapies are coming down anytime soon.
More Stories
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a...
Navigating Distrust: Pharma in the Age of Social Media
Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies...
Pharmaceutical Executive: February 2025 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive February 2025 issue in an interactive PDF format.
FDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes
Meilog marks the first rapid-acting insulin biosimilar to gain FDA approval for the treatment of diabetes.
Limitations of Modern Databases: Q&A with Stavros Papadopoulos
The TileDB CEO discusses how the life sciences can overcome these limitations.
Preparing for Potential Vaccine Regulatory Changes
James Foster, CEO and co-founder of Virax Biolabs, discusses how the industry is preparing for potential regulatory changes to vaccine...